Yao Houzong

Mr. Yao Houzong


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SNShuaijian Ni
Shuaijian Ni
YYao Houzong
Yao Houzong
LWLili Wang
Lili Wang
JLJun Lu
Jun Lu
FJFeng Jiang
Feng Jiang
GZGe Zhang
Ge Zhang
Nucleic acid aptamers have minimal immunogenicity, high chemical synthesis production, low cost and high chemical stability when compared with antibodies. However, the susceptibility to nuclease degradation, rapid excretion through renal filtration and insufficient binding affinity hindered their development as drug candidates for therapeutic applications. In this review, we will discuss methods to conquer these challenges and highlight recent developments of chemical modifications and technological advances that may enable early aptamers to be translated into clinical therapeutics.

9 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
FLFangfei Li
Fangfei Li
JLJun Lu
Jun Lu
JLJin Liu
Jin Liu
CLChao Liang
Chao Liang
MWMaolin Wang
Maolin Wang
GZGe Zhang
Ge Zhang
Paclitaxel (PTX) is among the most commonly used first-line drugs for cancer chemotherapy. However, its poor water solubility and indiscriminate distribution in normal tissues remain clinical challenges. Here we design and synthesize a highly water-soluble nucleolin aptamer-paclitaxel conjugate (NucA-PTX) that selectively delivers PTX to the tumor site. By connecting a tumor-targeting nucleolin aptamer (NucA) to the active hydroxyl group at 2′ position of PTX via a cathepsin B sensitive dipeptide bond, NucA-PTX remains stable and inactive in the circulation. NucA facilitates the uptake of the conjugated PTX specifically in tumor cells. Once inside cells, the dipeptide bond linker of NucA-PTX is cleaved by cathepsin B and then the conjugated PTX is released for action. The NucA modification assists the selective accumulation of the conjugated PTX in ovarian tumor tissue rather than normal tissues, and subsequently resulting in notably improved antitumor activity and reduced toxicity.

Verified
Journal Article
Open access
PDF file
ZMZiyuan Meng
Ziyuan Meng
QLQuanxia Lv
Quanxia Lv
JLJun Lu
Jun Lu
YYao Houzong
Yao Houzong
XLXiaoqing Lv
Xiaoqing Lv
GZGe Zhang
Ge Zhang
Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule modifications and macromolecule modifications have been developed by many research groups from all over the world. In this review, we discuss the different strategies especially prodrug strategies that are currently used to make paclitaxel more effective.

6 August 2020 in Inorganic Chemistry
Verified
Journal Article
Closed access
YYao Houzong
Yao Houzong
SCShu Chen
Shu Chen
ZDZhiqin Deng
Zhiqin Deng
MTMan-Kit Tse
Man-Kit Tse
YMYudai Matsuda
Yudai Matsuda
Guangyu ZhuGuangyu Zhu
Guangyu Zhu

Verified
Journal Article
Open access
PDF file
YYao Houzong
Yao Houzong
FJFeng Jiang
Feng Jiang
ALAiping Lu
Aiping Lu
GZGe Zhang
Ge Zhang
Antibody-drug conjugates (ADCs) have become a promising targeted therapy strategy that combines the specificity, favorable pharmacokinetics and biodistributions of antibodies with the destructive potential of highly potent drugs. One of the biggest challenges in the development of ADCs is the application of suitable linkers for conjugating drugs to antibodies. Recently, the design and synthesis of linkers are making great progress. In this review, we present the methods that are currently used to synthesize antibody-drug conjugates by using thiols, amines, alcohols, aldehydes and azides.

3 August 2020 in Inorganic Chemistry
Verified
Journal Article
Closed access
SCShu Chen
Shu Chen
YYao Houzong
Yao Houzong
QZQiyuan Zhou
Qiyuan Zhou
MTMan-Kit Tse
Man-Kit Tse
YGYuliana F. Gunawan
Yuliana F. Gunawan
Guangyu ZhuGuangyu Zhu
Guangyu Zhu